Table 1.
Cox proportional hazards analysis of factors associated with spontaneous HCV clearance during recent infection, excluding treated participants with an estimated duration of infection <26 weeks (n=132).
| Characteristic | Hazards Ratio | 95% | CI | P | Adjusted Hazards Ratio | 95% | CI | P |
|---|---|---|---|---|---|---|---|---|
| Age (yrs), mean/SD | - | - | - | - | - | - | - | - |
| Age category/10 years | 0.87 | 0.59 | 1.28 | 0.470 | - | - | - | - |
| Sex | ||||||||
| Male | 1.00 | - | - | - | 1.00 | - | - | - |
| Female | 1.04 | 0.48 | 2.22 | 0.925 | 1.23 | 0.56 | 2.68 | 0.601 |
| Injecting drug use | ||||||||
| Not injected in last 6 months | 1.00 | - | - | - | - | - | - | - |
| Injected in last 6 months | 0.81 | 0.30 | 2.22 | 0.689 | - | - | - | - |
| Never injected | 0.70 | 0.19 | 2.62 | 0.598 | - | - | - | - |
| Methadone or buprenorphine treatment | ||||||||
| No | 1.00 | - | - | - | - | - | - | - |
| Yes | 1.31 | 0.49 | 3.49 | 0.584 | - | - | - | - |
| Presentation of recent HCV | ||||||||
| Asymptomatic seroconversion | 1.00 | - | - | - | 1.00 | - | - | - |
| Acute clinical (no jaundice) | 0.90 | 0.30 | 2.71 | 0.845 | 0.90 | 0.30 | 2.71 | 0.846 |
| Acute clinical (with jaundice) | 2.75 | 1.21 | 6.24 | 0.016 | 2.86 | 1.24 | 6.59 | 0.014 |
| Estimated duration of infection (wks)* | ||||||||
| < 26 weeks | 1.00 | - | - | - | - | - | - | - |
| ≥ 26 weeks | 0.42 | 0.20 | 0.87 | 0.020 | - | - | - | - |
| Peak ALT prior to enrolment (IU/L) | ||||||||
| ≤ 400 | 1.00 | - | - | - | - | - | - | - |
| > 400 | 1.79 | 0.85 | 3.78 | 0.127 | - | - | - | - |
| HIV infection | ||||||||
| No | 1.00 | - | - | - | - | - | - | - |
| Yes | 0.83 | 0.35 | 1.92 | 0.657 | - | - | - | - |
| HCV genotype | ||||||||
| Genotype 1,4 | 1.00 | - | - | - | - | - | - | - |
| Genotype 2/3 | 0.93 | 0.28 | 3.07 | 0.909 | - | - | - | - |
| Missing | 20.79 | 7.58 | 57.03 | 0.000 | - | - | - | - |